Absolutely possible. AMBS could generate RUO revenue in 2015 which will drive up Lympro value and negotiating stance. AMBS with a consulting company could prepare Lympro for FDA approval and basically put it up for sale during CLIA market selling at end of 2015-16. They could pretend they are seeking a partner but my bet is they would be potentially shopping around for a sale. At that point the diagnostics would be long spun off and generating revenue. A buyer would get a nice package of Lympro Alzheimer's, Lympro TBI/CTE and NuroPro. That would be very attractive and big dollars.